Skip to main content

Month: June 2020

NoHo Partners has completed co-operation negotiations on continuing temporary layoffs due to the uncertain market situation

NoHo Partners PlcSTOCK EXCHANGE RELEASE 15 June 2020 at 13:15On 15 May 2020, NoHo Partners announced it would start co-operation negotiations on continuing temporary layoffs due to the uncertain market situation. The purpose of the negotiations was to predict the financial and production impacts caused by the coronavirus pandemic and adapt to the changed operating environment. The negotiations concerned all of the Group’s employees in Finland, totalling approximately 1,300 employees.The negotiations on continuing temporary layoffs have been completed. As a result of the negotiations, the continuation of the layoffs, either full-time or part-time, currently concerns approximately 550 employees. The temporary layoffs will last 90 days at most.The final number of laid-off employees and the duration of the layoffs will be specified further...

Continue reading

RedHill Biopharma soumet une demande d’essai clinique dans le cadre de l’étude de phase 2/3 sur l’opaganib dans le traitement de la maladie COVID-19

L’étude clinique multicentrique, randomisée, en double aveugle, à bras parallèle et contrôlée par placebo de phase 2/3 sur l’opaganib chez des patients atteints d’une forme grave de COVID-19 devrait être menée en Russie et dans d’autres pays, notamment en Europe—En parallèle, une étude clinique de phase 2a sur l’opaganib pour traiter des patients atteints d’une forme grave de COVID-19 est en cours de lancement aux États-UnisTEL-AVIV, Israël et RALEIGH, Caroline du Nord, 15 juin 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq : RDHL) (« RedHill » ou la « Société »), société biopharmaceutique spécialisée, a annoncé aujourd’hui avoir déposé une demande d’essai clinique (DEC) auprès du ministère de la Santé de la Fédération de Russie pour une étude clinique de phase 2/3 évaluant...

Continue reading

RedHill Biopharma reicht Zulassungsantrag für klinische Phase-II/III-Studie zur Behandlung von COVID-19 mit Opaganib ein

Die multizentrische, randomisierte, doppelblinde und placebokontrollierte klinische Parallelarmstudie der Phase II/III zur Behandlung von schwer erkrankten COVID-19-Patienten mit Opaganib soll in Russland und weiteren europäischen und außereuropäischen Ländern durchgeführt werden—Parallel dazu wird in den USA eine klinische Phase-IIa-Studie zur Behandlung von schwer erkrankten COVID-19-Patienten mit Opaganib eingeleitetTEL-AVIV, Israel und RALEIGH, N.C., June 15, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) („RedHill“ oder das „Unternehmen“), ein spezialisiertes biopharmazeutisches Unternehmen, hat heute bekanntgegeben, dass es beim russischen Gesundheitsministerium einen CTA-Antrag (Clinical Trial Application) für eine klinische Phase II/III-Studie zur Bewertung von Opaganib (Yeliva®, ABC294640)1 für die...

Continue reading

Coda Octopus Group Reports Fiscal 2020 Second Quarter and First Half Year Financial Results

ORLANDO, FL, June 15, 2020 (GLOBE NEWSWIRE) — Coda Octopus Group, Inc. (CODA) (Nasdaq: CODA) today reported its unaudited financial results for its fiscal second quarter ended April 30, 2020 and the first half of the 2020 fiscal year.Annmarie Gayle, CODA’s Chairman and CEO commented: “Although in the fiscal second quarter our business operations, and those of many of our customers, were severely curtailed due to the unprecedented global health, economic, and containment challenges brought about by the coronavirus pandemic, we have managed to limit our losses while, at the same time, conserving cash. We have also progressed a number of our defense projects which are key for our growth prospects. These include Phase II development of the Diver Augmented Vision Display (DAVD) system and the first delivery of small-batch production...

Continue reading

May 2020’s Most Wanted Malware: Ursnif Banking Trojan Ranks On Top 10 Malware List for First Time, Over Doubling Its Impact On Organizations

SAN CARLOS, Calif., June 15, 2020 (GLOBE NEWSWIRE) — Check Point Research, the Threat Intelligence arm of Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading provider of cyber security solutions globally, has published its latest Global Threat Index for May 2020.  Researchers found several malicious spam campaigns distributing the Ursnif banking trojan, which caused it to jump up 19 places to 5th in the Top Malware list, doubling its impact on organizations worldwide.The Ursnif banking trojan targets Windows PCs and is capable of stealing vital financial information, email credentials and other sensitive data. The malware is delivered in malicious spam campaigns via Word or Excel attachments. The new wave of Ursnif trojan attacks – which saw it enter the Top Malware index’s top 10 for the first time – coincides with...

Continue reading

Rubicon Organics Announces Supply Agreements With AGLC (Alberta) and BCLDB (British Columbia) & Achieves Sales Access to All of Western Canada

VANCOUVER, British Columbia, June 15, 2020 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (CSE:ROMJ) (OTCQX:ROMJF) (“Rubicon Organics” or the “Company”) is pleased to announce that it has signed supply agreements with both Alberta Gaming, Liquor & Cannabis (“AGLC”) and the British Columbia Liquor Distribution Branch (“BCLDB”) for the sale and distribution of Simply BareTM Organic cannabis to provincial and private cannabis retailers. Rubicon Organics, together with its distribution arrangement with Agro-Greens Natural Products Ltd. (“Agro-Greens”), now sells its products to all four western Canadian provinces and Ontario.“Building a direct supply relationship with the BCLDB is critical to success in our home province of British Columbia and will allow Rubicon Organics to more quickly fulfill and deliver orders” stated Jesse McConnell,...

Continue reading

Smart Sand, Inc. Regains Compliance With Nasdaq Listing Standards

THE WOODLANDS, Texas, June 15, 2020 (GLOBE NEWSWIRE) — Smart Sand, Inc. (NASDAQ: SND) (the “Company”) announced today that it has received notification from the Nasdaq Stock Market (“Nasdaq”) that the Company has regained compliance for continued listing on Nasdaq.On May 14, 2020, the Company was notified by Nasdaq that for 30 consecutive business days preceding the date of the notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on Nasdaq pursuant to Nasdaq minimum bid price requirements. On June 11, 2020, the Company was notified by Nasdaq that for 10 consecutive business days from May 28, 2020 through June 10, 2020, the bid price of the Company’s common stock had closed at or above $1.00 per share and the Company had regained compliance with the Nasdaq...

Continue reading

Targa Resources Corp. to Participate in J.P. Morgan Virtual Energy, Power & Renewables Conference

HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) — Targa Resources Corp. (NYSE: TRGP) (“Targa” or the “Company”) announced today that representatives from the Company will participate in investor meetings at the J.P. Morgan Virtual Energy, Power & Renewables Conference via video conference on Tuesday, June 16, 2020 and Wednesday, June 17, 2020.A copy of the slides used for the conference meetings will be available in the Investors section of the Company’s website at www.targaresources.com, or by going to https://www.targaresources.com/investors/events.About Targa Resources Corp.Targa Resources Corp. is a leading provider of midstream services and is one of the largest independent midstream energy companies in North America. The Company owns, operates, acquires and develops a diversified portfolio of complementary...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.